Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Sun Pharmaceutical Industries

Sun Pharmaceutical Industries

BSE: 524715|NSE: SUNPHARMA|ISIN: INE044A01036|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Sep 20, 16:00
506.45
-10.15 (-1.96%)
VOLUME 496,925
LIVE
NSE
Sep 20, 15:57
505.50
-10.3 (-2%)
VOLUME 5,024,913
News on Sun Pharmaceutical Industries
Select Year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Sun Pharma gets USFDA approval for new label for Odomzo

10.44 am | 20 Sep 2017 |  Source: Moneycontrol.com

Sun Pharmaceutical Industries' wholly owned subsidiaries has received approval from thernUS Food and Drug Administration (FDA) for a new label for...

Top pharma names should be looked at, says Basant Maheshwari 

8.28 am | 16 Sep 2017 |  Source: CNBC-TV18

Basant Maheshwari of Basant Maheshwari Wealth is of the view that pharma should be looked at but advises starting from the top notch companies, the bl...

Sun Pharma rallies 4% as Credit Suisse upgrades to outperform, sees 23% upside 

11.11 am | 14 Sep 2017 |  Source: Moneycontrol.com

Key risks according to Credit Suisse are Halol resolution delay, Dadra Form 483, and Department of Justice (DOJ) penalty....

Nifty likely to open lower, crucial support at 10022; buy Sun Pharma, REC

8.17 am | 14 Sep 2017 |  Source: Moneycontrol.com

Prakash Gaba of prakashgaba.com is of the view that market may go into a consolidation. The crucial support for the Nifty is at 10028-9996 and the res...

Sell Sun Pharmaceutical Industries; target of Rs 413: Geojit Research

4.50 pm | 13 Sep 2017 |  Source: Moneycontrol.com

Geojit Research is bearish on Sun Pharmaceutical Industries has recommended sell rating on the stock with a target price of Rs 413 in its research rep...

Sun Pharma dips 4% as CLSA says valuations expensive, margin pressure to continue

5.00 pm | 06 Sep 2017 |  Source: Moneycontrol.com

CLSA said building on speciality product pipeline is a strategy in the right direction but monetisation of speciality product pipeline is some time aw...

Top buzzing stocks to trade on September 6 

12.33 pm | 06 Sep 2017 |  Source: CNBC-TV18

Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today - Just Dial, Sun Pharmaceutical Industries, Ageis Logistics, Bhara...

Buy Sun Pharmaceutical Industries on dips, says Shahina Mukadam 

2.51 pm | 30 Aug 2017 |  Source: CNBC-TV18

Shahina Mukadam, Independent Market Expert is of the view that one may buy Sun Pharmaceutical Industries on dips....

Buy, Sell, Hold: 1 stock and 2 sectors are on the radar of investors today

9.15 am | 29 Aug 2017 |  Source: CNBC-TV18

Sun Pharma, among others, are being tracked by analysts on Tuesday....

Buy Sun Pharmaceutical Industries; target of Rs 550: KRChoksey

3.16 pm | 17 Aug 2017 |  Source: Moneycontrol.com

KRChoksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 550 in its research report dat...

DRL's legal trouble not serious; neutral on Sun Pharma: HDFC Securities 

10.14 am | 14 Aug 2017 |  Source: CNBC-TV18

In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about the latest happenings in Dr Reddy's Laboratories and the overall pharma s...

Pharma weekly wrap: Pharma stocks had tough week due to GST and pricing pressures in US

2.00 pm | 12 Aug 2017 |  Source: Moneycontrol.com

The news highlights in the sector include first quarter results of Sun Pharma, Aurobindo Pharma, Cipla, Cadila Healthcare among others. The US pricing...

Sun Pharma posts Q1 loss at Rs 425 cr on Modafinil settlement; US, India drag revenue 25% 

3.58 pm | 11 Aug 2017 |  Source: Moneycontrol.com

Revenue from operations in Q1 fell 24.8 percent to Rs 6,209 crore compared with Rs 8,256 crore in corresponding quarter of last fiscal, dented by US b...

Sun Pharma: Outcome of board meeting

3.45 pm | 11 Aug 2017 |  Source: Moneycontrol.com

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Financial...

Sun Pharma Q1 profit seen down 44% to Rs 1,144 cr on pricing pressure in US

12.16 pm | 11 Aug 2017 |  Source: CNBC-TV18

Operating profit is likely to crash 40 percent to Rs 1,744.5 crore and margin may contract 1,080 basis points to 24.6 percent compared with same quart...

SPARC Q1 net loss widens to Rs 78.84 cr

4.15 pm | 05 Aug 2017 |  Source: PTI

Total income of the company however rose to Rs 24.62 crore as against Rs 24.50 crore for the same period a year ago....

Sun Pharma Q1 PAT may dip 24.69% YoY to Rs 1713.2 cr: KR Choksey

6.42 pm | 18 Jul 2017 |  Source: Moneycontrol.com

Net Sales are expected to decrease by 2.39 percent Q-o-Q (down 16.79 percent Y-o-Y) to Rs 6662 crore, according to KR Choksey. Sun Pharma to report ne...

Buy Sun Pharma; target of Rs 650: Motilal Oswal

3.49 pm | 15 Jun 2017 |  Source: Moneycontrol.com

Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 650 in its research report dated June 14, 201...

Hold Sun Pharmaceuticals; target of Rs 549: ICICI Direct

5.19 pm | 29 May 2017 |  Source: Moneycontrol.com

ICICI Direct recommended hold rating on Sun Pharmaceuticals with a target price of Rs 549 in its research report dated May 29, 2017....

Buy Sun Pharmaceuticals; target of Rs 680: Edelweiss

3.42 pm | 29 May 2017 |  Source: Moneycontrol.com

Edelweiss is bullish on Sun Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 680 in its research report dated May 26,...

1 2 3
Quick Links for Sun Pharmaceutical Industries
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.